Category: Assay Development and Screening

1078-D - “Reduced animal usage and decreased study cost through microsampling approaches during preclinical safety testing”

Tuesday, February 6, 2018
5:00 PM - 6:00 PM

Pharmacokinetic and pharmacodynamic safety testing relies heavily upon small animal models during the preclinical phase. Promising lead compounds are typically administered to an animal cohort and blood is drawn across various time and/or compound dose courses. Current assay approaches demand significant blood sample volumes, often requiring multiple animals per data course or in extreme cases as many as one animal per data point, adding to experimental variability and overall study cost.

Assay miniaturization can reduce animal usage by enabling smaller blood draws and, therefore, an increased number of data points generated per animal. This approach we refer to as “microsampling”. We demonstrate that assay miniaturization using Labcyte Echo® Acoustic Liquid Handling Technology enables blood sampling to be reduced by 5 to 50-fold resulting in 60-80% reduction in animal needs. Combined with reductions in compound consumption and decreases in study length, microsampling approaches can afford up to 80% reduction in overall study cost, and fulfills the ethical need to reduce animal usage overall.

John Lesnick

Applications Manager
Labcyte Inc.
San Jose, CA

John Lesnick has worked in the Drug Discovery and Development field for over 20 years. He has contributed assay development expertise for many therapeutic areas from target validation to preclinical toxicology. His expertise with cell biology and biochemical molecular pharmacology has been applied to applications in genomics and drug discovery. John has extensive knowledge in automation and instrumentation and is currently an Applications Manager at Labcyte Inc.

Being based in the San Francisco bay area, John has led key technology initiatives that are transforming the way science is conducted in several applications including: Synthetic Biology, Genotyping, Next Generation Sequencing, Single Cell Analysis, High Throughput and High Content Screening, Functional Screening for Personalized Medicine, Diagnostic testing, Biomarker Discovery and more.